Milan Paul KUBELAC

CSII - Medicine

Fields of interest/specialization: Oncology, clinical trials, evolutionary medicine

Dr. Paul Kubelac is a primary physician in Medical Oncology, also certified through the European ESMO Examination working also at the Institute of Oncology “Prof. Dr. Ion Chiricuta” in Cluj-Napoca, Romania. His PhD in Medical Sciences is focused on evolutionary perspectives in ovarian cancer. Dr. Kubelac has published more than 44 ISI indexed articles, 5 books and worked in 12 research grants. Dr. Kubelac was a ESMO Fellow Awardee that worked at Institut Gustave Roussy, Paris with Dr. Alexandra Leary in the Gynecological Department. Other relevant positions include investigator and sub-investigator in multiple Phase I-III clinical trials and a representative for his Institution within the EURACAN network, subdomain of rare gynaecological cancers.

Curriculum Vitae: CV Kubelac

Google Scholar: https://scholar.google.ro/citations?user=dBzi93cAAAAJ&hl=ro

ResearchGate: https://www.researchgate.net/profile/Paul-Kubelac

Representative works:

Achimas-Cadariu P, Kubelac PM, Pasca A, Gata VA, Fetica B, Balacescu O, Fischer-Fodor E, Focsan M, Astilean S, Vlad CI. Intraoperative imaging of residual ovarian cancer after neoadjuvant chemotherapy using indocyanine green. Int J Gynecol Cancer. 2024 Nov 4:ijgc-2024-005568.
Xu-Vuillard A, Guerin-Charbonnel C, Bocquet F, Cheeseman S, Kubelac PM, Zenatri M, Hall G, Achimas-Cadariu P, Hanvic B, Fenton H, Sturz-Lazăr AM, Augereau P, Ray-Coquard I, Leary A, Frenel JS. Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer. ESMO Open. 2024 Sep;9(9):103694.
Preda AC, Ciuleanu TE, Todor N, Vlad C, Iancu DI, Mocan C, Bandi-Vasilica M, Albu F, Todor-Bondei IM, Hapca MC, Kubelac MP, Kubelac-Varro AD. Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment-The Experience of Ion Chiricuță Oncology Institute. Cancers (Basel). 2024 May 26;16(11):2022.
Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim D, et al. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. Frontiers in Oncology. 2023;13.
Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, Rühli F. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present. J Ovarian Res. 2022;15(1).
Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, et al. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. Cancers. 2020;12(3).
Achimas-Cadariu P, Iancu M, Kubelac P, Pop F, Braicu I, Vlad C, et al. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III. Eur J Cancer Care (Engl). 2017;26(6).